Human medicines European public assessment report (EPAR): Rybelsus, semaglutide, Date of authorisation: 03/04/2020, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Rybelsus, semaglutide, Date of authorisation: 03/04/2020, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Evkeeza, evinacumab, Date of authorisation: 17/06/2021, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Evkeeza, evinacumab, Date of authorisation: 17/06/2021, Revision: 10, Status: Authorised

Quality Innovation Group (QIG) Listen and Learn Focus Group (LLFG) meeting on personalised medicines, Online, European Medicines Agency, Amsterdam, the Netherlands, from 8 April 2025, 10:00 (CEST) to 9 April 2025, 15:30 (CEST)

Quality Innovation Group (QIG) Listen and Learn Focus Group (LLFG) meeting on personalised medicines, Online, European Medicines Agency, Amsterdam, the Netherlands, from 8 April 2025, 10:00 (CEST) to 9 April 2025, 15:30 (CEST)

Human medicines European public assessment report (EPAR): Vyloy, zolbetuximab, Date of authorisation: 19/09/2024, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Vyloy, zolbetuximab, Date of authorisation: 19/09/2024, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 28, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness